Please sign in to follow a disease.
Which ablation device works best for irregular heartbeat? large trial aims to find out
NCT ID NCT07456540
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will compare different pulse field ablation systems used to treat atrial fibrillation (AF), a common heart rhythm problem. Over 1,100 patients will receive one of the standard treatments depending on the time period they are treated. Researchers will track whether AF returns within 12 months and check for complications within 30 days. The goal is to find out which system is safest and most effective.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Pulse field ablation systems (devices used during catheter ablation)
- What this could lead to
- If successful, this could identify which ablation system works best to prevent atrial fibrillation from returning, improving treatment choices.
- What could go wrong
- This is an early-stage comparison study, not a test of a new cure. Results may show no clear winner, and individual outcomes vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,125 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 years or older * Planned Catheter Ablation of Atrial Fibrillation with Pulmonary Vein Isolation Exclusion Criteria: \- Opt out of data collection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Rigshospitalet
Copenhagen, 2100, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercise tame atrial fibrillation? trial tests workouts on heart rhythm and fitness
- Pacemaker lead position may cut heart rhythm complication
- Can zapping the heart beat drugs for AF in heart failure?
- Heart hole or stroke trigger? global registry tracks who gets closure and what happens next
- Two ways to quiet a racing heart: trial pits hybrid ablation against standard catheter treatment
- Stroke's hidden heart rhythm clue under investigation